For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic hepatitis B covalently closed circular DNA. For its primary hyperoxaluria type 1 program ...

in the ELIMINATE-B Phase I trial for curing chronic hepatitis B by targeting covalently closed circular DNA (cccDNA), the virus's replicative element. The company is currently recruiting subjects ...